RADCOM Ltd.: RADCOM Announces Preliminary Second Quarter Revenue and Updated Full-Year Guidance

RADCOM Ltd. (NASDAQ: RDCM) said it expects Q2 2026 revenue of about $12 million due to customer deployment delays tied to higher component costs and supply constraints. It reduced full-year 2026 revenue guidance to $57-$63 million (midpoint $60 million) and expects non-GAAP profitability. Q2 results are scheduled for Aug. 12.

Original reporting
Published Jul 30, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$RDCM
Bearish
medium confidence
Mentioned
$RDCM
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$RDCMBearishMed
01

Why it matters

Preliminary Q2 revenue and a reduced full-year 2026 revenue range indicate a near-term revenue timing issue tied to customer deployments, with management expecting profitability to remain intact on a non-GAAP basis.

02

Market read

Traders can reprice RADCOM ahead of the Aug 12 earnings release based on the disclosed preliminary revenue and the narrowed, lower full-year outlook.

03

What to watch

The company says no cancellations or competitive losses, but the market will focus on cash flow timing and whether the non-GAAP profitability assumption remains intact in final results.

Relevance 8/10Novelty 7/10Timing: ahead of Aug 12 pre-market earnings release

Background

RADCOM is an assurance and observability software provider for telecom networks, reporting quarterly results with guidance updates.

Company-level read

Ticker impact

$RDCMBearishMedium confidence
Context

RADCOM cut its full-year 2026 revenue outlook to $57-$63M after preliminary Q2 revenue of about $12M from customer deployment delays.

Expected impact

Likely negative bias for the stock into the Aug 12 earnings print, with volatility around whether final results confirm the preliminary revenue and margin outlook.

Evidence & confidence

The article discloses specific preliminary revenue and a reduced full-year range, which typically drives repricing even if management frames it as timing-only. Confirmation risk remains until the Aug 12 release.

Market effects

Could pressure sentiment for telecom assurance and AIOps vendors if investors extrapolate deployment delays into the sector’s near-term spending cycle.

Limited direct regional read-through beyond Israel-linked tech risk sentiment.

Mostly company-specific; broader impact depends on whether similar telecom equipment/software buyers are also delaying deployments.

Counterpoint

If delays are truly timing-related and collections/margins hold, the guidance cut may be less damaging than it looks and could set up an upside surprise versus conservative expectations.

Key entities

  • RADCOM Ltd.

    NASDAQ-listed telecom assurance and AIOps provider issuing preliminary Q2 revenue and updated full-year 2026 guidance.

  • Benny Eppstein

    CEO cited customer deployment delays impacting purchasing decisions and revenue timing.

  • Hod Cohen

    CFO referenced in contact details for the earnings release process.

Related articles

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.

$GXOMed

GXO Logistics Q2 Earnings Call Highlights

GXO Logistics reported Q2 results and said it secured over $1 billion in expected incremental new-business revenue for 2026 and about $353 million for 2027. Management cited a $2.7 billion sales pipeline after quarter end. Operating cash flow was $76 million, free cash flow positive $12 million, cash $769 million, and net leverage 2.6x. GXO plans to target EBIT margins above 6% and deploy AI across ~50 sites in 2026.

$GRNDMed

Grindr Q2 Earnings Call Highlights

Grindr (NYSE:GRND) said free users remain central to its strategy, while AI tools are boosting engineering productivity. Management estimated engineering output rose about 2.5x from July 2025 to April 2026 with similar headcount, supporting a 39% to 42% adjusted EBITDA margin outlook. EDGE AI premium tier rollout is planned for later in fall; operating expenses ex cost of revenue were $71M vs $53M.

$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.